Cephalon, Inc. (CEPH)
An international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat human diseases. Currently its four core therapeutic areas are central nervous system disorders, pain, cancer and addiction.
Recs
scoobamang
(86.36)
Submitted: 11/7/2009 10:02:26 PM :
Start Price:
$58.18
CEPH Score:
-7.10
Good fundamentals for a big company in the pharmaceutical industry. Increasing revenue and profit and near 52 week low.
Recs
MagicDiligence
(83.00)
Submitted: 11/5/2009 7:11:07 AM :
Start Price:
$57.27
CEPH Score:
-7.81
Cephalon has three drugs with good growth potential. If sales develop according to the company's plan, the current price will prove to be a bargain.
http://www.magicdiligence.com/articles/cephalon-CEPH-review-2009-11-05
Recs
kkconway
(90.10)
Submitted: 10/22/2009 3:36:22 PM :
Start Price:
$54.83
CEPH Score:
+0.10
Tough year for a proven winner; drugs in pipeline give it a 'shot' for a turnaround.
Recs
tsperbeck
(98.76)
Submitted: 10/15/2009 12:48:27 PM :
Start Price:
$55.01
CEPH Score:
-0.50
Caps 5* ready to break out.
Recs
08PortfolioModel
(< 20)
Submitted: 9/19/2009 7:47:25 PM :
Start Price:
$56.93
CEPH Score:
-9.85
Current 58.49, Sept 18 09. Limit 57.00
Recs
JDKeene
(92.63)
Submitted: 8/12/2009 1:01:32 PM :
Start Price:
$57.12
CEPH Score:
-12.92
Ford Strong Buy, S&P (4 or 3 stars), Member of S&P 500
Recs
darksabre
(39.46)
Submitted: 7/29/2009 11:57:37 AM :
Start Price:
$58.97
CEPH Score:
-20.21
zzlangerhans, five stars CAPS, lags S&P
Recs
Recs
Teknowizz
(88.04)
Submitted: 5/8/2009 12:01:16 PM :
Start Price:
$65.20
CEPH Score:
-36.11
Top fundamentals in their industry
Recs
Alex1963
(97.34)
Submitted: 4/22/2009 11:09:36 AM :
Start Price:
$65.26
CEPH Score:
-45.64
5* Caps An international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat human diseases. Currently its four core therapeutic areas are central nervous system disorders, pain, cancer and addiction.
LTD/equity.69, excellent efficiency numbers, mgt, profitability, strong growth & growth history. 52 week H/L $59.45-$81.35. beta under 1.
Recs
zzlangerhans
(99.52)
Submitted: 2/27/2009 1:11:40 AM :
Start Price:
$69.29
CEPH Score:
-68.38
Just as Obama enthusiasm for stem cell stocks is senseless, Obama pessimism for pharmaceuticals is overblown. I don't believe his policies will fundamentally change the business model or profitability of mid-to-large cap biotechs, and I see this as another opportunity to green thumb some quality companies at depressed prices.
Recs
gdcalc
(73.41)
Submitted: 2/19/2009 3:10:22 PM :
Start Price:
$73.59
CEPH Score:
-68.55
Held in mutual fund, real money.
Recs
tickertale
(69.06)
Submitted: 2/2/2009 10:11:57 PM :
Start Price:
$77.83
CEPH Score:
-64.57
looking for a break-out to new highs...and a run at $100.
Recs
WilliamCrook2007
(< 20)
Submitted: 11/20/2008 2:33:00 PM :
Start Price:
$72.57
CEPH Score:
-66.92
IBD
Recs
homdet
(< 20)
Submitted: 11/14/2008 7:29:49 PM :
Start Price:
$74.15
CEPH Score:
-57.07
This Company has a number of strengths, which I believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most
stocks. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, notable return on equity, reasonable valuation levels and good cash flow from operations.
Recs
vmirage
(89.86)
Submitted: 10/27/2008 10:37:01 AM :
Start Price:
$64.11
CEPH Score:
-44.90
Cephalon's deal with Acusphere will yield mega profits if ACUS's drug Imagify is approved by the FDA in the next coming months.
Recs
ipowerdg
(< 20)
Submitted: 10/12/2008 2:14:03 PM :
Start Price:
$64.23
CEPH Score:
-33.92
Continued growth in core drug roducts and strong research and product pipeline.
Recs
TekATL08
(< 20)
Submitted: 9/8/2008 4:17:37 PM :
Start Price:
$76.39
CEPH Score:
-17.25
Great Pipeline and new uses of existing pipeline of drugs being tested and found.
Recs
stick703
(< 20)
Submitted: 7/29/2008 11:22:58 AM :
Start Price:
$73.52
CEPH Score:
-16.04
CEPH will beat earnings expectations today.
Recs
ramram50
(< 20)
Submitted: 4/14/2008 12:33:52 PM :
Start Price:
$63.20
CEPH Score:
+1.75
CHEAP AND TAKEOVER CANDIDATE
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 35 1 2 Next »